表纸
市场调查报告书

糖生物学的全球市场:各产品类型、应用、终端用户、地理的成长率,趋势及预测(2018年~2023年)

Glycobiology Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 661003
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
糖生物学的全球市场:各产品类型、应用、终端用户、地理的成长率,趋势及预测(2018年~2023年) Glycobiology Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

糖生物学,预计从2018年到2023年的预测期间内,以约13%的年复合成长率成长。糖生物学,是生命科学重要的领域,包含在细菌生理学的研究,新药物的开发及蛋白质体学研究中发挥多样作用的糖锁链的研究。研究人员为了糖锁链应用,活用质谱分析,MALDI-TOF等各种技术。因此,含质谱仪及MALDI-TOF质谱仪的糖生物学设备的需求,预计不久的将来将增加。

本报告提供全球糖生物学市场调查,整体市场趋势,各产品、地区的详细趋势,市场成长的影响要素分析,竞争情形,主要企业简介等,总括性汇整。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要推论

第5章 市场概要

  • 目前市场方案
  • 波特的五力分析
    • 供应商谈判力
    • 消费者谈判力
    • 新加入厂商的威胁
    • 替代产品与服务的威胁
    • 产业内的竞争

第6章 成长要素,阻碍因素,机会,课题分析(DROC)

  • 市场成长要素
    • 政府及民间对糖生物学及蛋白质体学研究的资金筹措增加
    • 医药品及生物科技企业的研究开发费的增加
  • 市场阻碍因素
    • 高的产品成本
    • 熟练专家的低可用性
  • 市场机会
  • 主要课题

第7章 市场区隔

  • 各产品
    • 酵素
    • 器具
    • 套件
    • 试剂
  • 各应用领域
    • 诊断
    • 药物研发开发
    • 肿瘤学
    • 免疫学
    • 其他
  • 终端用户
    • 医药品及生物科技企业
    • 契约研究机关(CRO)
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第8章 竞争情形

  • M&A分析
  • 协定,合作,伙伴关系
  • 新产品的销售

第9章 主要企业

  • Agilent Technologies
  • Bruker Corporation
  • Danaher Corporation
  • Merck KGaA
  • New England Biolabs
  • ProZyme
  • 岛津制作所
  • TaKaRa BIO
  • Thermo Fisher Scientific
  • Waters Corporation 等

第10章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 53251

The glycobiology market will show rapid growth due to the increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies.

  • The major pharmaceutical and biotech companies are heavily investing in the research and development of superior biological products, such as glycobiology products and products related to proteomics.
  • There is also an increased demand for curative treatments for many life-threatening diseases, such as cancer, which is expected to drive the pace of pharmaceutical and biotechnological R&D, as well as overall investments made in glycobiology field. This makes glycobiology an attractive option for big pharma and biotech companies to invest in. Furthermore, glycomic biomarkers have significant applications in drug development and diagnostics for many diseases.
  • In addition, a huge amount of investment is put into the development of its products and the approval of drugs that are developed, require a lot of regulatory stages that are necessary for the process. This, in turn, renders these products very expensive.

Key Market Trends

Drug Discovery and Development is Expected to be the Largest Growing Segment

On the basis of application, drug discovery and development has been accounted for the largest market share. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. There is an increasing R&D investments by pharmaceutical companies, which increases the drug discovery and development of glycomics. For instance, R&D expenditure of Merck accounted for USD 9.8 billion, in 2018.

The other applications segment is anticipated to witness the high CAGR due to rising clinical trials and R&D expenses incurred by key companies for research.

North America is Found Leading the Glycobiology Market

North America has been accounted for the largest market share due to the presence of key pharmaceutical and biopharmaceutical companies. The presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, there is also increasing applications of glycans in various cancers and increasing funds from the government in enhancing the field of glycobioogy, that helps the market to grow over the forecast period.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies undertaken by these companies for sustainable growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
    • 4.2.2 Growing R&D Expenditure by Pharmaceutical and

Biotechnology Companies

  • 4.3 Market Restraints
    • 4.3.1 High Product Cost
    • 4.3.2 Low Availability of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Enzymes
    • 5.1.2 Instruments
    • 5.1.3 Kits
    • 5.1.4 Reagents
  • 5.2 By Application
    • 5.2.1 Diagnostics
    • 5.2.2 Drug Discovery and Development
    • 5.2.3 Oncology
    • 5.2.4 Immunology
    • 5.2.5 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Research Organizations
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Bruker Corporation
    • 6.1.3 Danaher Corporation
    • 6.1.4 Merck KGaA
    • 6.1.5 New England Biolabs
    • 6.1.6 ProZyme
    • 6.1.7 Shimadzu Corporation
    • 6.1.8 Takara Bio
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top